Tradestie Institutional Equity Comparison Engine

EDIT vs PACB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EDIT Overall Edge

EDIT Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Editas Medicine, Inc. Common Stock (EDIT) driven by superior Growth & Margin, Options & Structure while PACB counters with relative strength in Momentum & Technical. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus PACB at N/M Forward P/E and -333.0% operating margin (+5.5% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against PACB sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EDIT N/M vs PACB N/M Fwd P/E
Growth & Margin Winner EDIT
Op Margin -167.0% vs -333.0% ยท YoY +37.4% vs +5.5%
Momentum & Technical Winner PACB
1Y -25.0% vs +15.6% ยท 52W Pos 11% vs 34%
Options & Structure Winner EDIT
BREAKDOWN (38th %ile IV) vs BREAKDOWN (47th %ile IV)
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
1M Return -18.94%
1Y Return -25.0%
Forward P/E N/M
Unified AI Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.89
-3.83% 1D
Market Cap $615.1M
1M Return +8.96%
1Y Return +15.64%
Forward P/E N/M
Unified AI Score
38.0 / 100 SELL
Tech 15.0 Fund 35.0 Flow 57.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EDIT -25.0% PACB +15.64% Spread: +40.64 pp (PACB Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period EDIT Revenue PACB Revenue EDIT Op. Margin PACB Op. Margin Margin Edge
FY2018 $30M $80M -356.1% -128.4% PACB
FY2019 $20M $90M -686.4% -110.6% PACB
FY2020 $90M $80M -148.6% -132.3% PACB
FY2021 $30M $130M -756.1% -161.2% PACB
FY2022 $20M $130M -1146.3% -239.4% PACB
FY2023 $80M $200M -216.6% -166.8% PACB
FY2024 $30M $150M -777.2% -308.0% PACB
FY2025 $40M $160M -394.9% -346.2% PACB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EDIT (5) vs PACB (3)
Institutional Metric EDIT PACB Criterion Row Winner
Market Capitalization Scale $336.5M $615.1M Larger Scale PACB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +37.4% +5.5% Higher Growth EDIT
Operating Margin (TTM) Profitability -167.0% -333.0% Higher Margin EDIT
Net Profit Margin Profitability -144.9% -81.3% Higher Margin PACB
Return on Equity (ROE) Capital Efficiency -147.4% -929.3% Higher ROE EDIT
52-Week Range Position Momentum 11% ($2โ€“$4) 34% ($1โ€“$3) Stronger Trend PACB
Beta / 30D Volatility Risk Regime 2.32ฮฒ ยท 102% Vol 2.27ฮฒ ยท 112% Vol Lower Realized Risk EDIT
Unified Institutional Score Composite Signal 51.6 / 100 (HOLD) 38.0 / 100 (SELL) Higher Composite EDIT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EDIT vs PACB Buy Guide
EDIT BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EDIT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 47th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live PACB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EDIT nor PACB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.